Abstract:Objective Resistance toward imatinib and other BCR/ABL tyrosine kinase inhibitors(TKI) remains an increasing clinical problem in the treatment of advanced stages of chronic myeloid leukemia (CML). Heme oxygenase-1 (HO-1) inhibition plus TKI were found to produce growth inhibition in imatinib-resistant K562/IM cells and in Ba/F3 cells harboring the T315I mutant of BCR/ABL. In this study, we aimed to explore the molecular mechanism of HO-1 explosive expression and relationship between HO-1 and Protein Kinase C-βII(PKC-βII) in imatinib-resistant CML cells. Methods We explored that mRNA expression of various drug-resistant-relative gene between K562 cells and K562/IM cells via high throughout screening assay detected by real-time PCR. According to the results mentioned above, relative protein expression and phosphorylation examined by western blot. And protein translocation was observed and recorded by fluorescence microscope. Cells apoptosis, reactive oxygen species(ROS) and intracellular calcium were analyzed by flow cytometry. Cells proliferation inhibition was detected by CCK-8 assay. The peripheral blood mononuclear cells(PBMNCs) were purified from 45 patients with freshly diagnosed CML or imatinib-resistant CML(including all kinds of drug-resistance involved in various of reasons). Compared the differences of mRNA expression between HO-1 and PKC-βII in those patients. Results Our results indicated that PKC-βII contributed to activation of HO-1 expression through PI3K/AKT pathway. PKC-βII phosphorylation localized to membrane from cytoplasim to activate PI3K/AKT pathway, meanwhile, the 7.8 folder higher (p<0.01) expression of HO-1 following the nucleus translocation of NF-E2–related factor 2(Nrf-2) was observed after pAKT up-regulation. The accumulation of ROS and intracellular calcium overload were reduced by HO-1 to protect cells against cytotoxicity, less apoptotic imatinib-resistant K562 cells were detected at the same concentration of imatinib(the total apoptotic rate of K562/IM:42.4%±3.3% vs. K562: 72.1%±4.1%, at the concentration of 1 μM, p<0.01). In addition, the results of HO-1 and PKC-βII mRNA expression in PBMNCs from 45 patients indicated that HO-1 activation kept positively correspondent with expression of PKC-βII in primary leukemic cells obtained from those patients. In addition, blockage of PI3K/AKT, silence of PKC-βII or HO-1 by small interfere RNA( or inhibited by targeted inhibitor) could significantly increase apoptotic rate of imatinib-resistant CML cells(the apoptotic rate of regulated expression/ natural expression: when blockage of PI3K/AKT: 1.54±0.17; silence of PKC-βII: 2.09±0.23; inhibition of HO-1: 1.87±0.12, p<0.05). Conclusion Selectively targeted-PKC-βII plus imatinib produced growth inhibition in primary leukemic cells. In summary, these data showed that HO-1 expression involved in PKC-βII activation in imatinib-treated CML cells, and targeted- PKC-βII may be the same promising novel strategy as HO-1 inhibition in imatinib resistant CML. Disclosures: No relevant conflicts of interest to declare.

CX‑5461 Potentiates Imatinib‑induced Apoptosis in K562 Cells by Stimulating KIF1B Expression.

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

Stromal Cells Attenuate the Cytotoxicity of Imatinib on Philadelphia Chromosome-Positive Leukemia Cells by Up-Regulating the VE-cadherin/β-catenin Signal

Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation

Imatinib and Bortezomib Induce the Expression and Distribution of Anaphase-Promoting Complex Adaptor Protein Cdh1 in Blast Crisis of Chronic Myeloid Leukemia.

Coordination of Intrinsic, Extrinsic, and Endoplasmic Reticulum-Mediated Apoptosis by Imatinib Mesylate Combined with Arsenic Trioxide in Chronic Myeloid Leukemia.

Synergistic Cytotoxicity from Combination of Imatinib and Platinum-Based Anticancer Drugs Specifically in Bcr-Abl Positive Leukemia Cells.

BIM Induction of Apoptosis Triggered by EGFR-sensitive and Resistance Cell Lines of Non-Small-cell Lung Cancer

CAY10683 and Imatinib Have Synergistic Effects in Overcoming Imatinib Resistance Via HDAC2 Inhibition in Chronic Myeloid Leukemia.

C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells

A Combination of STI571 and BCR-ABL1 Sirna with Overexpressed P15ink4b Induced Enhanced Proliferation Inhibition and Apoptosis in Chronic Myeloid Leukemia

Tanshinone IIA Potentiates the Efficacy of Imatinib by Regulating the AKT-MDM2-P53 Signaling Pathway in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

KPT-330 Inhibition of Chromosome Region Maintenance 1 is Cytotoxic and Sensitizes Chronic Myeloid Leukemia to Imatinib

Protein Kinase C-βii-Dependent Up-Regulation of Heme Oxygenase-1 in Chronic Lymphocytic Leukemia Cells is Crucial for Resistance Against Imatinib

Targeting BCL6 in gastrointestinal stromal tumor promotes p53-mediated apoptosis to enhance the antitumor activity of imatinib

Proteasome Inhibitor/Imatinib Combinations Exert Potentiated Antileukemia Efficacy But Not Cardiotoxicity In Chronic Myeloid Leukemia

Inhibition of IGF-IR Tyrosine Kinase Induces Apoptosis and Cell Cycle Arrest in Imatinib-Resistant Chronic Myeloid Leukaemia Cells.

Lycorine attenuated proliferation and induced apoptosis on imatinib-resistant K562 cell by inhibiting autophagy

[Effect of ZD6474 on the Proliferation of Imatinib-Resistant K562 Cells].